Oxford, United Kingdom

e­-therapeutics is a drug discovery company with a proprietary network­ driven drug discovery platform, which uses using artificial intelligence (AI), machine learning and other computational techniques.


Investment Perspective

e-therapeutics ended its FY19 (year-ending 31 January 2019) on a high, securing its first commercial collaboration with Novo Nordisk in December (see Update note). Business development and cost control were the focus areas for FY19. The Novo deal in Type 2 diabetes marked a first success on the former, providing important validation for e-therapeutics’ proprietary Network-Driven Drug Discovery (NDD) platform. Prudent cost management means end-FY19 cash of £5.9m, coupled with an anticipated £1.1m tax credit, provides a two-year runway on our estimates. The goal is to now capitalise on ongoing, and new, business development discussions covering the full range of e-therapeutics’ assets and capabilities, to help progress NDD-derived projects and further exploit the NDD platform. Our valuation is £57.8m (21.9p/share).

Market information

Symbol Primary exchange Currency
Last Price Market Cap
52 Week Low 52 Week High


Setting the stage
Update | 06 Mar 2019
First commercial deal secured with global diabetes leader
Update | 10 Dec 2018
New insights from Parkinson’s disease collaboration
Update | 06 Dec 2018

Recent News

Notice of AGM and annual report
08 Mar 2019
FY19 results
05 Mar 2019
Research Collaboration with Novo Nordisk
10 Dec 2018
Initial results of C4X Parkinson’s Disease Collaboration
06 Dec 2018